Protective effect of vitamin C on 8-hydroxy-2′-deoxyguanosine level in peripheral blood lymphocytes of chronic hemodialysis patients  by Tarng, Der-Cherng et al.
Kidney International, Vol. 66 (2004), pp. 820–831
Protective effect of vitamin C on 8-hydroxy-2′-deoxyguanosine
level in peripheral blood lymphocytes of chronic
hemodialysis patients
DER-CHERNG TARNG, TSUNG-YUN LIU, and TUNG-PO HUANG
Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan; and Division of Nephrology, Department
of Medicine and Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan
Protective effect of vitamin C on 8-hydroxy-2′-deoxyguanosine
level in peripheral blood lymphocytes of chronic hemodialysis
patients.
Background. This study focused on the effect of vitamin C
on the 8-hydroxy-2′-deoxyguanosine (8-OHdG) level of cellu-
lar DNA, as well as 8-oxoguanine-DNA glycosylase 1 (hOGG1)
and human MutT homologue (hMTH1) gene expression in pe-
ripheral blood lymphocytes of chronic hemodialysis patients.
Methods. Sixty chronic hemodialysis patients (35 men and
25 women) were recruited to participate in a randomized,
placebo-controlled study. Treatment order is block-randomized
with intravenous sodium ascorbate (vitamin C, 300 mg) or
placebo (0.9% saline), administered postdialysis three times
a week. We evaluated 8-OHdG level, intracellular reactive
oxygen species (ROS) production, and gene expression of
hOGG1 and hMTH1 in peripheral blood lymphocytes by
using high-performance liquid chromatography (HPLC) elec-
trochemical detection method, flow cytometric analysis, and
reverse transcription-polymerase chain reaction (RT-PCR),
respectively.
Results. A total of 51 patients completed the study (26 in
placebo group and 25 in vitamin C group). Mean 8-OHdG lev-
els significantly decreased in total subjects following 8 weeks of
vitamin C supplementation (22.9 vs. 18.8/106 dG, P < 0.01). The
decrease in 8-OHdG levels after vitamin C supplementation
was also noted in the patients with ferritin <500 or ≥500 lg/L
and transferrin saturation (TSAT) <50 or ≥50% (P < 0.05). But
8-OHdG levels had no significant changes in total patients or in
the four subgroups of patients treated with placebo as compared
to their baselines. Intracellular ROS production by lymphocytes
from the four subgroups of patients, either spontaneous (P <
0.05) or phorbol-12-myristate-13-acetate (PMA)-stimulated (P
< 0.001), was significantly reduced after 8 weeks vitamin C sup-
plementation. Steady-state hOGG1 mRNA levels were signifi-
cantly up-regulated at 24 hours after vitamin C administration
(P < 0.05), but hMTH1 mRNA levels were not. The changes in
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the spontaneous and PMA-stimulated ROS production, and an
up-regulation of hOGG1 mRNA expression were not observed
in patients treated with placebo as compared to their baselines.
Conclusion. Vitamin C supplementation in chronic
hemodialysis patients can reduce the lymphocyte 8-OHdG
levels and intracellular ROS production, as well as up-regulate
hOGG1 gene expression for repair. There is no compelling
evidence for an in vivo pro-oxidant effect of vitamin C
on lymphocyte DNA base oxidation, even in the status of
increased iron stores.
Cumulative data have shown that oxidative damage
to biomolecules such as DNA, lipids, and proteins has
been implicated as a causal factor for a number of com-
plications in patients undergoing chronic hemodialysis
[1–3]. Cellular DNA is particularly susceptible to oxida-
tive injury in chronic hemodialysis patients because there
is an imbalance between reactive oxygen species (ROS)
and antioxidant defenses [4, 5], or repair enzymes [6].
Of the more than 20 different oxidative DNA base le-
sions, 8-hydroxy-2′-deoxyguanosine (8-OHdG) appears
to be the most abundant and mutagenic [7, 8]. 8-OHdG
has emerged as a novel marker for the assessment of
oxidative DNA damage in ROS-mediated diseases [9,
10]. Our recent works have further demonstrated that
8-OHdG contents in cellular DNA provide a reliable
measure of steady-state oxidative DNA damage in pe-
ripheral blood leukocytes for chronic hemodialysis pa-
tients [4, 5]. Increased leukocyte 8-OHdG levels are
elicited by the abundant ROS elaborated from leukocytes
with metabolic activation after blood-membrane contact
during hemodialysis [5, 11]. The augmented DNA oxida-
tion is further aggravated by the impaired oxidant scav-
enging system of plasma as substantiated by decreased
plasma levels of vitamins C and E and glutathione in
chronic hemodialysis patients [4–6].
Vitamin C (ascorbate) is depleted in the fluids in vivo
under conditions of oxidative stress such as smoking [12]
and inflammation associated with rheumatoid arthritis
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[13]. Hemodialysis has also been shown to decrease
antioxidant defenses, which results in an increased re-
quirement of chronic hemodialysis patients for the
supplementation of vitamin C, the main hydrophilic
antioxidant of the body [14, 15]. Recently, therapeutic ap-
proaches based on parenteral administration of vitamin C
have received increasing attention in most hemodialysis
units to promote better anemia control and iron utiliza-
tion. The beneficial effect on recombinant erythropoietin
response can be observed not only for chronic hemodial-
ysis patients with normal iron status [16], but also for
those having a high ferritin level of >500 to 800 lg/L [17–
19]. Theoretically, vitamin C scavenges ROS and reac-
tive nitrogen species and may thereby prevent oxidative
damage to important biologic macromolecules. Investi-
gators reported that an increase in lipid peroxidation is
prevented by administration of high doses of vitamin C
(504 mg per session) during hemodialysis using a tradi-
tional dialyzer of cellulose membrane [15]. However, to
our best knowledge, there is no study to examine whether
vitamin C exhibits a protective role in DNA oxidation for
chronic hemodialysis patients. In contrast, vitamin C can
act as a pro-oxidant by reduction of redox active tran-
sition metal ions (i.e., iron and copper) through Fenton
chemistry. The availability of catalytic transition metals
in human blood may be the key factor in determining vi-
tamin C-related oxidative paradox [13, 20]. Since vitamin
C administration facilitates iron mobilization in chronic
hemodialysis patients [16–19], it potentially might be haz-
ardous, especially in those with iron overload. In such pa-
tients, vitamin C might promote electron exchange and
enhance iron toxicity to cellular constituents. Therefore,
the aims of the present study is to elucidate whether vita-
min C acts as an antioxidant in vivo to attenuate oxidative
DNA damage in lymphocytes of chronic hemodialysis pa-
tients, or paradoxically as a pro-oxidant to amplify DNA
oxidation.
Repair of DNA that contains oxidized bases or other
abnormal bases is essential for maintaining the accuracy
of genetic information. In mammalian cells, 8-OHdG
causes misreading through G to T and A to C transver-
sions, which are reported to be responsible for its muta-
genicity [8–10]. Therefore, cells recognize 8-OHdG as a
threatening lesion that requires rapid removal. Repair of
DNA containing oxidized bases involves complex path-
ways at both the blood and cellular levels. Multiple re-
pair mechanisms that remove 8-OHdG from DNA [21,
22], or prevent its incorporation into DNA [23, 24], have
evolved. 8-Oxoguanine-DNA glycosylase 1 (hOGG1)
and human MutT homologue (hMTH1) are two repre-
sentative enzymes for repair of its respective nucleotide
8-hydroxyguanine (8-OHG) [21–24]. In healthy subjects
receiving vitamin C supplementation, Cooke et al [25]
observed a significant increase in the levels of serum
and urine 8-OHdG, measured using competitive enzyme-
linked immunosorbent assay (ELISA) method. This find-
ing has been inferred as being due to stimulation of DNA
repair enzymes by vitamin C. Therefore, to determine in
vivo effects of vitamin C on the major lesion of DNA
base oxidation and regulation of gene expression for its
repair enzymes, 8-OHdG contents in cellular DNA and
intracellular ROS production, as well as mRNA expres-
sion of hOGG1 and hMTH1 were measured in periph-
eral blood lymphocytes of chronic hemodialysis patients
before and after supplementation of vitamin C. In addi-
tion, the changes in these parameters were analyzed in
our patients having a serum ferritin level of >500 lg/L or
transferrin saturation (TSAT) of >50%.
METHODS
Patients and study protocol
To assess whether or not vitamin C supplementation
has an in vivo antioxidant effect on cellular DNA of pe-
ripheral blood lymphocytes, a total of 60 patients (35 men
and 25 women) undergoing chronic hemodialysis at
the two dialysis centers of our affiliated hospital were
recruited to participate in a prospective, randomized,
placebo-controlled study. Exclusion criteria included
age <20 years; duration on hemodialysis protocols for
<3 months before the study; habit of tobacco smoking;
disorders such as diabetes mellitus, malignancy, chronic
inflammatory diseases and acute infections; consumption
of vitamin C or E; and treatment with oral or intravenous
iron supplements, angiotensin-converting enzyme (ACE)
inhibitors or anti-inflammatory drugs 3 months prior to
enrollment. The causes for chronic renal failure were
glomerulonephritis (N = 24), interstitial nephritis (N =
11), nephrosclerosis (N = 11), polycystic kidney disease
(N = 6), and shrunken kidney with unknown etiology
(N = 8). Their mean age was 58 ± 12 years and av-
erage duration on hemodialysis was 46 ± 25 months.
Dialytic procedure was a standard bicarbonate session,
performed with single-use dialyzers equipped with cel-
lulose membrane (Terumo, Tokyo, Japan) of 1.75 m2 ef-
fective surface area. Hemodialysis was performed three
times weekly for 12 to 13.5 hours/week. Dialysis ma-
chines were sterilized daily, and water treatment cir-
cuits and tanks were sterilized weekly. The colony count
of microorganisms in water used to prepare dialysis
fluid did not exceed 200 colonies/mL. Endotoxin levels
in dialysate, detected weekly by amebocyte lysate test
(LAL) (Chromogenix, Charleston, SC, USA), were less
than 0.01 EU/mL.
The randomized, placebo-controlled study was carried
out for 8 weeks. In the 8-week period, chronic hemodial-
ysis patients were randomly assigned to receive supple-
mentation with vitamin C or normal saline (placebo).
Treatment order is block-randomized with the use of
computerized-generated random numbers. Ten milliliters
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of sodium ascorbate (total vitamin C, 300 mg) or 10 mL
of 0.9% saline was administered intravenously for 5 min-
utes postdialysis three times weekly for 8 weeks. Blood
samples were taken on two occasions, before supplemen-
tation started and after 8 weeks supplementation. All pa-
tients fasted for 12 hours immediately before the blood
samples were taken. Any ongoing medications were con-
tinued without changes in dosage during the study. The
patients were also required to complete a 3-day food di-
ary, which was used to estimate the daily intake of vitamin
C before the investigation and at the study completion
[26]. The protocol was approved by the Committee on
Human Research at Taipei Veterans General Hospital.
Informed consent was obtained from each of the study
subjects.
Laboratory measurements
In each study subject, whole blood was collected by
venipuncture predialysis and divided into aliquots for
the subsequent analyses to be performed. For transferrin
bound iron levels and iron-binding capacity blood serum
was analyzed and for ascorbic acid determination plasma
samples were separated. An aliquot of 1 mL plasma was
mixed with 1 mL of 100 g/L metaphosphoric acid (MPA)
and stored at −70◦C until measurement of ascorbate con-
centration. In addition, 2 mL of blood was withdrawn into
a heparinized vacutainer tube for flow cytometric analy-
sis of intracellular ROS production by lymphocytes, and
10 mL of blood was withdrawn into an ethylenedi-
aminetetraacetic acid (EDTA)-containing vacutainer for
isolation of lymphocytes. Lymphocytes were separated
from 10 mL of whole blood on Ficoll-Hypaque den-
sity gradients, washed twice in phosphate-buffered saline
(PBS) (pH 7.4), and centrifuged again. The cells recov-
ered were confirmed to be 95% lymphocytes and frozen
at −70◦C until use for determination of 8-OHdG content
in the cellular DNA.
Iron in serum was determined using the commercial
kit by an autoanalyzer (Hitachi 736−60) (Naka, Japan).
Total iron-binding capacity was measured by the TIBC
Microtest (Daiichi, Tokyo, Japan) and serum ferritin
by radioimmunoassay (Incstar, Stillwater, MN, USA).
Transferrin saturation (TSAT) was calculated as the
serum iron concentration/TIBC × 100. Serum C-reactive
protein (CRP) was measured by an immunoturbidimetric
assay using a rate nephrelometry (Beckman, Galway, Ire-
land). Plasma ascorbate was measured by a method de-
scribed by Kyaw [27]. In brief, color reagent was prepared
by mixing 0.3 mmol/L sodium tungstate, 1.2 mmol/L
sodium hydrogen phosphate, and 18 mol/L sulfuric acid.
One mL of color reagent was slowly added into 0.5 mL of
MPA-treated plasma. After thoroughly and slowly mix-
ing, the mixture was allowed to stand for 30 minutes at
room temperature and then centrifuged at 1000 × g for
15 minutes. The blue-colored supernatant was transferred
to another test tube, and absorbance at 700 nm was read
against a blank constituted with distilled water. For every
set, a standard (1 mg/dL ascorbic acid with 0.5% oxalic
acid) and a blank were run in parallel throughout the
procedure.
Measurement of 8-OHDG content
Total DNA of lymphocytes was extracted by the
pronase/ethanol method [28] with some modifications.
Briefly, nuclear fractions were obtained by centrifuga-
tion at 1000 × g for 10 minutes after gentle homoge-
nization of peripheral blood lymphocytes in 10 mL of
5 mmol/L Tris-HCl buffer (pH 7.6) containing 1% Tri-
ton X-100, 320 mmol/L sucrose and 10 mmol/L MgCl2.
The nuclear fraction was resuspended vigorously in
700 lL of standard sodium citrate (SSC) (5 mmol/L
sodium citrate and 20 mmol/L sodium chloride, pH 6.5).
After adding 200 lL of pronase E (20 mg/mL in SSC),
800 lL of Sarkosyl (1.5% in 20 mmol/L EDTA, and
20 mmol/L Tris-HCl, pH 8.5) and 100 lL of 5% butylated
hydroxytoluene (BHT) in methanol, the mixture was in-
cubated for 6 hours at 45◦C. After incubation, following
the addition of 800 lL of TE buffer (10 mmol/L Tris-HCl
and 1 mmol/L EDTA, pH 7.5) and 200 lL of 7.5 mol/L am-
monium acetate, cooled ethanol (−20◦C) was carefully
added up to 70% while mixing. Precipitated DNA was
stored overnight in 95% ethanol containing 0.01% BHT.
The amount of 8-OHdG was measured by the method
using high-performance liquid chromatography (HPLC)
equipped with an EC detector (Bioanalytical Systems,
West Lafayette, IN, USA) as described previously [4–
6, 29]. Deoxyguanosine (dG) (Sigma Chemical Co., St.
Louis, MO, USA) and 8-OHdG were used as standards.
The 8-OHdG level is expressed as the number of 8-OHdG
molecules per 106 dG. Intraassay coefficients of variance
(CV) ranged from 4% to 8% and interassay CV ranged
from 5% to 10%, where the lower numbers refer to the
CV for the high standard and the higher numbers refer
to the CV for the low standard.
Flow cytometric analysis of intracellular ROS production
Two 100 lL aliquots of each sample were analyzed
for ROS production, one at baseline and the other after
activation with phorbol-12-myristate-13-acetate (PMA)
(Sigma Chemical Co., St. Louis, MO, USA). Leuko-
cytes were harvested from blood samples after lysis of
red blood cells by a lysis solution (0.15 mol/L NH4Cl,
10 mmol/L NaHCO3, and 10 mM EDTA, pH 7.4). Af-
ter centrifugation for 10 minutes at 350 × g and 4◦C,
leukocyte pellet was suspended in 1.5 mL of Hanks’ bal-
anced salt solution (pH 7.3). Cell viability was determined
by trypan blue exclusion. Leukocytes were then incu-
bated at 37◦C for 5 minutes with 1.5 lL of 20 mmol/L
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2′,7′-dichlorofluorescin diacetate (DCF-DA) (Molecular
Probes, Eugene, OR, USA). After labeling, leukocytes
were incubated for 30 min at 37◦C in the presence
or absence of 100 ng/mL of PMA. Total leukocytes
were subjected to flow cytometry analysis (FACSort)
(Becton-Dickinson, San Jose, CA, USA) for measure-
ment of intracellular production of ROS (O2− and H2O2)
[30]. The lymphocyte population was determined by
gating on a forward scatter and side scatter dot plot
as described previously [11]. Intracellular ROS pro-
duction was expressed as mean fluorescence of 2′,7′-
dichlorofluorescein (DCF), a product liberated from
DCFH, which is hydrolyzed to nonfluorescent polar
derivative from DCF-DA by intracellular esterases, and
is highly fluorescent after oxidation by H2O2. ROS pro-
duction was then monitored every 10 minutes on FAC-
Sort by measuring the intensity of fluorescence emitted at
525 nm for DCF. Data for each sample were calculated by
the CellQuest software (Becton-Dickinson) on a power
Macintosh 6100/66 computer.
Reverse transcriptase-polymerase chain
reaction (RT-PCR)
Total RNA was extracted from lymphocyte (5 × 106)
using a RNA-zol kit (Cinna/Biotecx Laboratories Inter-
national Inc., Friendwood, TX, USA). First-strand cDNA
was synthesized by Ready-to-GoTM RT-PCR beads
(Amersham Pharmacia Biotech, Piscataway, NJ, USA)
using Moloney murine leukemia virus-derived reverse
transcriptase according to the procedure recommended
by the manufacturer. Complementary DNA was ampli-
fied in 100 lL total volume containing 50 mmol/L KCl,
20 mmol/L Tris-HCl (pH 8.0), 10 mmol/L deoxynucleo-
side triphosphate (dNTP), 1.5 mmol/L MgCl2, 1 U Taq
polymerase, and 10 pmol of specific PCR primers. The sets
of primers used for PCR amplification were 5′-ACTGTC
ACTAGTCTCACCAG-3′ (sense) and 5′-AGGGGAA
GGTGCTTG GGGGAA-3′ (antisense) for hOGG1
[31], yielding a 203 bp PCR product; and 5′-CTCAGCG
AGTTCTCCTGG-3′ (sense) and 5′-GGAGTGGAAAC
CAGT AGCTGTC-3′ (antisense) for hMTH1 [23], yield-
ing a 334 bp PCR product. Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was coamplified with primers
of 5′-CGGCGTCACGGATTTGGTC-3′ (sense) and 5′-
ACTGTGGTCATGAGTCC TTC-3′ (antisense), yield-
ing a 516 bp PCR product as the internal standard. The
thermoprofile consisted of 30 to 38 cycles of denaturation
at 94◦C for 15 seconds, annealing at 56◦C for 15 seconds,
and extension at 72◦C for 30 seconds, preceded by an
initial denaturation step at 94◦C for 2 minutes and fol-
lowed by a terminal extension of 5 minutes at 72◦C. The
number of cycles used allowed quantification without sat-
uration [32]. Amplification products were separated by
electrophoresis on 2% agarose gel, followed by ethidium
bromide staining, and then photographed. The amplifi-
cation bands were quantitated from the film negative by
scanning densitometry. Semiquantitation was done by se-
rial dilution of the input cDNA to measure the mRNA.
The proportion of specific gene product to GAPDH prod-
uct was used for semiquantitative analysis.
Statistical analysis
Statistical analysis was performed using the computer
software Statistical Package of Social Science, version 8.0
(1997; SPSS Inc., Chicago, IL, USA). Data are expressed
as mean values ± SD. Values for serum ferritin were not
normally distributed and reported as means with ranges.
Mann-Whitney rank sum test was used for comparison of
data from two groups and Pearson’s chi-square test for
frequency measures. Data for more than two groups were
analyzed using Kruskal-Wallis test, followed by multiple
comparison tests for significance of differences. Wilcoxon
singed ranks test was used for comparison of baselines
and data after treatment with vitamin C or placebo. The
relationships between 8-OHdG contents in lymphocyte
DNA and the potentially explanatory continuous vari-
ables were analyzed by Pearson’s correlation. A P value
of less than 0.05 is considered statistically significant.
RESULTS
Nine patients (five in the placebo group and four in
the vitamin C treatment group) had withdrawn by the
end of study because of cerebral infarct (N = 1), pneu-
monia (N = 2), arteriovenous access thrombosis (N =
3), and transfer to peritoneal dialysis (N = 1), and re-
nal transplantation (N = 2). Finally, a total of 51 patients
(26 in placebo group and 25 in vitamin C group) com-
pleted the study. In placebo group (N = 26), there were 14
patients with ferritin of <500 lg/L and 12 with ferritin of
≥500 lg/L, or 14 with TSAT of <50% and 12 with TSAT
of ≥50%. In vitamin C group (N = 25), there were 13
patients with ferritin of <500 lg/L and 12 with ferritin of
≥500 lg/L, or 15 with TSAT of <50% and 10 with TSAT
of ≥50% (Table 1). Patients treated with placebo or vi-
tamin C did not differ significantly from each other in
terms of age, gender distribution, duration of hemodial-
ysis, hemoglobin values, weekly dose of recombinant
erythropoietin, serum CRP, and causes of chronic renal
failure in the subgroups stratified by a cutoff value of
serum ferritin of 500 lg/L or TSAT of 50%. Mean di-
etary vitamin C intake of the subjects, as assessed by the
food diary, was optimal throughout the study and no sig-
nificant variation was observed within the study period.
Mean daily intake of vitamin C was 129 ± 58 mg/day
in total subjects and no significant difference was ob-
served between patients receiving placebo and vitamin
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Table 1. Characteristics of hemodialysis patients recruited in the study and of patients in the subgroups stratified by cutoff values of serum
ferritin of 500 lg/L and transferrin saturation (TSAT) of 50%
Patients with serum ferritin <500 lg/L Patients with serum ferritin ≥500 lg/L
Total Vitamin C Vitamin C
patients Placebo supplement P value Placebo supplement P value
Numbers 51 14 13 12 12
Age years 59 ± 13 59 ± 14 62 ± 12 0.665a 59 ± 15 56 ± 13 0.453a
Male number (%) 31 (60.8) 8 (57.1) 7 (53.8) 0.903b 8 (66.7) 8 (66.7) 1.000b
Hemodialysis duration months 46 ± 37 56 ± 47 46 ± 45 0.225a 40 ± 26 41 ± 26 0.707a
Vitamin C intake mg/day 129 ± 58 126 ± 57 135 ± 58 0.476a 121 ± 48 132 ± 69 0.536a
Hemoglobin g/dL 10.2 ± 1.4 10.6 ± 0.7 10.7 ± 1.7 0.216a 10.1 ± 0.9 9.9 ± 1.0 0.194a
Erythropoietin dose U/kg/week 92 ± 28 93 ± 19 96 ± 22 0.659a 87 ± 30 90 ± 22 0.357a
C-reactive protein mg/L 5.3 ± 9.4 5.6 ± 11.6 4.5 ± 8.6 0.951a 5.3 ± 7.2 6.0 ± 7.9 0.859a
Cause of renal failure
Glomerulonephritis number (%) 20 (39.2) 6 (42.9) 5 (38.5) 0.787b 5 (41.7) 4 (33.3) 0.913b
Interstitial nephritis number (%) 10 (19.6) 3 (23.0) 3 (23.1) 2 (16.7) 2 (16.7)
Nephrosclerosis number (%) 9 (17.6) 1 (7.1) 3 (23.1) 2 (16.7) 3 (25.0)
Polycystic kidneys number (%) 6 (11.8) 2 (14.3) 1 (7.7) 1 (8.3) 2 (16.7)
Unknown cause number (%) 6 (11.8) 2 (14.3) 1 (7.7) 2 (16.7) 1 (8.3)
Patients with TSAT <50% Patients with TSAT ≥50%
Vitamin C Vitamin C
Placebo supplement P value Placebo supplement P value
Numbers 14 15 12 10
Age years 60 ± 13 55 ± 12 0.190a 58 ± 16 65 ± 12 0.339a
Male number (%) 9 (64.3) 9 (60.0) 0.940b 7 (58.3) 6 (60.0) 0.867b
Hemodialysis duration months 44 ± 35 32 ± 27 0.247a 55 ± 44 60 ± 44 0.817a
Vitamin C intake mg/day 120 ± 43 130 ± 62 0.522a 128 ± 57 139 ± 48 0.666a
Hemoglobin g/dL 10.3 ± 0.6 9.8 ± 1.8 0.205a 10.2 ± 1.4 10.5 ± 0.9 0.598a
Erythropoietin dose U/kg/week 92 ± 38 93 ± 26 0.810a 88 ± 25 93 ± 30 0.517a
C-reactive protein mg/L 5.2 ± 9.6 5.3 ± 7.7 0.752a 5.7 ± 10.5 5.1 ± 10.6 0.896a
Cause of renal failure
Glomerulonephritis number (%) 5 (35.7) 5 (33.3) 0.586b 6 (50.0) 4 (40.0) 0.606b
Interstitial nephritis number (%) 2 (14.3) 1 (6.7) 3 (25.0) 4 (40.0)
Nephrosclerosis number (%) 2 (14.3) 6 (40.0) 1 (8.3) 0 (0.0)
Polycystic kidneys number (%) 2 (14.3) 1 (6.7) 1 (8.3) 2 (20.0)
Unknown cause number (%) 3 (21.4) 2 (13.3) 1 (8.3) 0 (0.0)
aMann-Whitney U test; bPearson’s chi-square test.
C supplement in the subgroups of patients (P > 0.05)
(Table 1).
Plasma ascorbate and serum iron indices
Overall, supplementation with vitamin C for 8 weeks
significantly increased plasma ascorbate concentration
from 43.7 ± 18.6 lmol/L to 88.4 ± 28.5 lmol/L (P <
0.001) (Table 2). Moreover, the increase was significant
irrespective of the presupplemental serum ferritin and
TSAT (42 ± 12 lmol/L to 87 ± 24 lmol/L in those with
ferritin of <500 lg/L (P < 0.005) and 45 ± 19.7 lmol/L
to 90 ± 33 lmol/L in those with ferritin of ≥500 lg/L
(P < 0.005); 42 ± 14 lmol/L to 87 ± 31 lmol/L in those
with TSAT of <50% (P < 0.005) and 46 ± 25 lmol/L to
91 ± 39 lmol/L in those with TSAT of ≥50% (P < 0.01).
In contrast, there were no significant changes in plasma
ascorbate concentration after treatment with placebo. As
compared with the presupplemental values, no signifi-
cant differences were observed in serum ferritin and iron
concentrations and TSAT after 8 weeks supplementation
either with vitamin C or with placebo. A trend to in-
crease TSAT and to decrease serum ferritin levels was
only noted in the patients with ferritin of ≥500 lg/L af-
ter 8 weeks of vitamin C supplementation, but it did not
reach statistical significance (P > 0.05) (Table 2).
Vitamin C reduced intracellular ROS production
of lymphocytes
To evaluate the activated oxygen metabolism of lym-
phocytes, the intracellular production of ROS in lympho-
cytes was analyzed by flow cytometry before and after
8 weeks supplementation either with vitamin C or with
placebo. The DCF fluorescence intensity was determined
for 30 minutes because the fluorescence increased almost
linearly up to 30 minutes. Within 30 minutes, the sponta-
neous ROS production increased above the initial level
in unstimulated lymphocytes from total subjects signifi-
cantly decreased after 8 weeks of supplementary vitamin
C (35 ± 33% to 7 ± 15%, P < 0.05) (Fig. 1). Significant
decreases in the spontaneous ROS production of unstim-
ulated lymphocytes were also observed in patients with
ferritin of <500 or ≥500 lg/L and with TSAT of <50%
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Table 2. Plasma ascorbate, serum ferritin, and iron concentrations and transferrin saturation (TSAT) before and after treatment in hemodialysis
patients
Patients with serum ferritin Patients with serum ferritin
Total patients <500 lg/L ≥500 lg/L
Time Vitamin C Vitamin C Vitamin C
weeks Placebo supplement Placebo supplement Placebo supplement
Vitamin C lmol/L 0 49.7 ± 35.9 43.7 ± 18.6 54.2 ± 38.1 42.2 ± 12.2 44.5 ± 28.9 45.3 ± 19.7
8 52.2 ± 42.0 88.4 ± 28.5 57.7 ± 43.8 87.2 ± 23.8 45.9 ± 34.3 89.7 ± 33.2
P = 0.420 P < 0.001 P = 0.470 P = 0.001 P = 0.715 P = 0.002
Serum ferritin lg/L 0 649 (28–2355) 667 (29–1826) 342 (28–496) 277 (29–478) 1008 (551–2355) 1089 (561–1826)
8 662 (28–2899) 574 (68–1753) 295 (28–480) 320 (68–482) 1090 (334–2899) 849 (295–1753)
P = 0.167 P = 0.475 P = 0.209 P = 0.136 P = 0.209 P = 0.084
Serum iron lg/dL 0 100 ± 41 94 ± 49 100 ± 45 107 ± 60 99 ± 36 80 ± 25
8 98 ± 59 89 ± 52 96 ± 61 90 ± 69 101 ± 58 89 ± 29
P = 0.737 P = 0.493 P = 0.660 P = 0.133 P = 0.859 P = 0.209
TSAT % 0 43 ± 17 38 ± 16 40 ± 16 42 ± 20 48 ± 19 35 ± 9
8 41 ± 22 36 ± 11 32 ± 11 32 ± 9 50 ± 27 39 ± 12
P = 0.124 P = 0.737 P = 0.096 P = 0.134 P = 0.583 P = 0.076
Patients with TSAT <50% Patients with TSAT ≥50%
Time Vitamin C Vitamin C
weeks Placebo supplement Placebo supplement
Vitamin C lmol/L 0 49.2 ± 42.1 42.1 ± 13.5 50.3 ± 31.4 46.0 ± 25.3
8 48.2 ± 32.0 86.5 ± 31.2 56.8 ± 29.9 91.3 ± 39.1
P = 0.929 P = 0.001 P = 0.728 P = 0.005
Serum ferritin lg/L 0 484 (28–1175) 650 (56–1324) 837 (49–2355) 691 (29–1826)
8 458 (28–768) 592 (68–1753) 900 (130–2899) 545 (135–1113)
P = 0.219 P = 0.460 P = 0.937 P = 0.859
Serum iron lg/dL 0 76 ± 21 74 ± 29 127 ± 40 124 ± 50
8 85 ± 49 76 ± 24 113 ± 65 109 ± 76
P = 0.675 P = 0.609 P = 0.530 P = 0.241
TSAT % 0 31 ± 5 27 ± 7 57 ± 7 54 ± 5
8 33 ± 11 29 ± 9 50 ± 11 47 ± 12
P = 0.510 P = 0.125 P = 0.272 P = 0.574
Comparison between baselines and 8 weeks by Wilcoxon signed rank test.
or ≥50% after vitamin C supplementation (P < 0.05).
But there was no significant difference after treatment
with placebo as compared to the baseline values. Like-
wise, the PMA-stimulated production of ROS by lym-
phocytes from chronic hemodialysis patients significantly
decreased after 8 weeks of supplementary vitamin C
(124 ± 44% to 61 ± 21%, P < 0.001) (Fig. 2). The decrease
in PMA-stimulated ROS production by lymphocytes af-
ter vitamin C supplementation was also observed in pa-
tients with ferritin of <500 or ≥500 lg/L and with TSAT
of <50% or ≥50% (P < 0.05). No significant changes
were noted in the PMA-stimulated ROS production by
lymphocytes after 8 weeks treatment with placebo.
Vitamin C attenuated oxidative DNA damage
of lymphocytes
Mean 8-OHdG contents in cellular DNA of lympho-
cytes significantly decreased following 8 weeks supple-
mentary vitamin C in total 25 subjects (22.9 ± 8.7 to 18.8 ±
8.3/106 dG, P < 0.01) (Fig. 3). The decrease was also noted
in the four subgroups of patients after supplementation
with vitamin C (17.2 ± 6.0 to 14.6 ± 7.1/106 dG in those
with ferritin of <500 lg/L, P < 0.05 and 29.1 ± 6.6 to
23.3 ± 7.3/106 dG in those with ferritin of ≥500 lg/L,
P < 0.05; 21.6 ± 9.4 to 17.2 ± 8.8/106 dG in those with
TSAT of <50%, P < 0.05 and 23.8 ± 8.3 to 17.8 ± 8.1/106
dG in those with TSAT of ≥50%, P < 0.05). But there
were no significant changes in mean 8-OHdG levels in
total 26 patients and in the four subgroups of patients
receiving placebo treatment as compared to their base-
line values. Lymphocyte 8-OHdG at baselines was signif-
icantly higher in vitamin C treated patients with ferritin
≥500 lg/L as compared to those with ferritin of <500 lg/L
(P < 0.05), but showed no significant differences in
placebo group with ferritin of <500 and ≥500 lg/L or
following 8 weeks of placebo and vitamin C treatment
(P >0.05) (Fig. 3). Univariate analysis disclosed that the
decrease in lymphocyte 8-OHdG levels after 8 weeks of
supplementary vitamin C significantly correlated with the
increase in plasma ascorbate, and the decrease in spon-
taneous and PMA-stimulated ROS production by lym-
phocytes in total 25 subjects and in the subgroups of
patients with ferritin of <500 or ≥500 lg/L and with
TSAT of <50% or ≥50% (Table 3). But these correla-
tions were not observed in 26 patients receiving placebo
treatment.
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Fig. 1. Spontaneous production of reactive oxygen species (ROS) in
unstimulated lymphocytes before () and 8 weeks after treatment ().
The percentages of increased in fluorescence above the resting level
within 30 minutes are shown in all chronic hemodialysis patients, pa-
tients with ferritin values of <500 and ≥500 lg/L, and patients with
transferrin saturation (TSAT) of <50 and ≥50%, respectively. Brack-
ets indicate SD. aP < 0.05 vs. 0 week by Wilcoxon signed rank test.
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Fig. 2. Phorbol-12-myristate-13-acetate (PMA)-induced production
of reactive oxygen species (ROS) in lymphocytes before () and 8
weeks after treatment (). The percentages of increased in fluores-
cence above the resting level within 30 minutes are shown in all chronic
hemodialysis patients, patients with ferritin values of <500 and ≥500
lg/L, and patients with transferrin saturation (TSAT) of <50 and ≥50%,
respectively. Brackets indicate SD. aP < 0.001; bP < 0.05 vs. 0 week by
Wilcoxon signed rank test.
Vitamin C up-regulated hOGG1 mRNA expression
in lymphocytes
To explore the effect of vitamin C on the mRNA lev-
els of DNA repair gene, first we compared the hOGG1
and hMTH1 mRNA levels of lymphocytes among normal
healthy subjects (N = 5), uremic patients not receiving
dialysis yet (N = 5), and chronic hemodialysis patients
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Fig. 3. 8-hydroxy-2′-deoxyguanosine (8-OHdG) contents in cellular
DNA of peripheral blood lymphocytes before () and 8 weeks after
treatment () in all chronic hemodialysis patients, patients with ferritin
values of<500 and ≥500 lg/L, and patients with transferrin saturation
(TSAT) of<50 and ≥50%, respectively. aP < 0.01; bP < 0.05 vs. 0 week
by Wilcoxon signed rank test.
(N = 20). Then we assessed the changes in hOGG1 and
hMTH1 mRNA expression for 24 hours after vitamin C
administration (300 mg) in chronic hemodialysis patients.
Lymphocyte 8-OHdG levels were highest in chronic
hemodialysis patients, followed by undialyzed patients
then by normal healthy controls (25.4 ± 8.5 vs. 12.5 ±
5.3 vs. 6.3 ± 4.7/106 dG, ANOVA P < 0.001). Steady-
state hOGG1 mRNA level significantly increased in
undialyzed patients, and further rose in chronic hemodial-
ysis patients (P < 0.01), increasing to 2.8-fold above
that of controls (Fig. 4). hMTH1 mRNA level of chronic
hemodialysis patients significantly increased to 2.1-fold
above that of controls (P < 0.05), but showed no signifi-
cant difference from that of undialyzed patients (Fig. 4).
Vitamin C treatment resulted in a time-dependent rise of
hOGG1 mRNA expression, increasing to twofold above
the baselines at 24 hours. In contrast, there was no
detectable effect on the levels of hMTH1 mRNA for
24 hours (data not shown). Overall, the administration of
vitamin C to chronic hemodialysis patients significantly
up-regulated hOGG1 mRNA levels at 24 hours in those
with ferritin of <500 lg/L (N = 10) and of ≥500 lg/L
(N = 10) (P < 0.05) (Fig. 5), but the change in hMTH1
mRNA levels was not observed. There was no effect
of placebo treatment on the expression of hOGG1 or
hMTH1 mRNA at 24 hours in chronic hemodialysis pa-
tients (Fig. 5). Twenty chronic hemodialysis patients were
reanalyzed and stratified by TSAT of <50% (N = 14)
and of ≥50% (N = 6). An up-regulation of hOGG1
mRNA levels at 24 hours was also observed after the ad-
ministration of vitamin C to both subgroups of patients
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Table 3. Univariate analysis of the relationship between changes of 8-hydroxy-2′-deoxyguanosine (8-OHdG) contents and potentially
explanatory continuous variables after 8 weeks of vitamin C supplementation
All Ferritin Ferritin TSAT TSAT
Patients <500 lg/L ≥500 lg/L <50% ≥50%
Variable (N = 25) (N = 13) (N = 12) (N = 15) (N = 10)
Plasma ascorbate −0.649b −0.473a −0.456a −0.543a −0.477a
Spontaneous ROS production 0.486a 0.558a 0.325 0.512a 0.392
(% of baseline within
30 minutes) in lymphocytes
PMA-induced ROS production 0.634b 0.567a 0.488a 0.600a 0.516a
(% of baseline within
30 minutes) in lymphocytes
Serum ferritin 0.162 0.233 0.156 0.107 0.276
Serum iron 0.212 0.148 0.271 0.284 0.105
TSAT 0.321 0.281 0.357 0.145 0.122
Abbreviations are: PMA, phorbol-12-myristate-13-acetate; ROS, reactive oxygen species; TSAT, transferrin saturation; , difference between before treatment and
8 weeks after treatment for each variable. Univariate analysis is performed using Pearson correlation. Lymphocyte 8-OHdG and serum ferritin values are not normally
distributed and are thus transformed by natural logarithm. Data are expressed as correlation coefficient (r).
aP < 0.05.
bP < 0.005.
(P < 0.05), but the change in hMTH1 mRNA levels was
still not noted.
DISCUSSION
Oxidatively induced DNA damage in peripheral blood
leukocytes is known to be increased in end-stage renal
disease (ESRD) patients receiving hemodialysis [4–6].
In this study, we further demonstrated that oxidative
DNA damage, as assessed using the novel marker of
8-OHdG in peripheral blood lymphocytes, is increased
in both chronic hemodialysis and nondialyzed patients,
and more elevated in the former. The level of 8-OHdG
measured in lymphocytes is an integration of a number
of parameters, including the cellular redox status, antiox-
idant defense mechanisms, and ROS production. Oxida-
tive stress is increased in chronic hemodialysis patients,
and peripheral blood neutrophils and lymphocytes may
be an important source for ROS due to metabolic acti-
vation after blood-membrane contact during hemodial-
ysis [5, 11]. Protection from oxidant injury involves
complex pathways at both the blood and cellular levels.
Vitamin C acts as a potent water-soluble antioxidant in
biologic fluid by scavenging pathologically relevant ROS
and reactive nitrogen species [13, 20]. Our previous data
expressing significantly decreased plasma level of ascor-
bate provide insight into the defective redox status in
chronic hemodialysis patients [4–6]. These findings are
in line with the investigations of decreased plasma con-
centration of vitamin C in chronic hemodialysis patients
due to increased consumption caused by increased oxida-
tive stress, loss through dialysis process, and inadequate
dietary intake [33, 34]. Accordingly, increased oxidative
DNA damage in lymphocytes may in part result from
low vitamin C and increased hemodialysis-derived oxi-
dants. In this study the most compelling finding shows that
vitamin C decreased lymphocyte 8-OHdG contents and
markedly reduced intracellular ROS production by lym-
phocytes, either spontaneous or PMA-stimulated, in both
chronic hemodialysis patients with normal and increased
iron stores (Figs. 1 to 3). The correlation of decreases in
8-OHdG in DNA with increases in plasma vitamin C con-
centration following supplementation (Table 3) suggests
strongly a protective role of vitamin C against oxidative
DNA damage.
The human data on the role of vitamin C in protect-
ing against oxidatively induced DNA damage are con-
troversial and appear inconsistent. Some investigators
have reported a reduction in ex vivo or in vivo DNA
oxidation in lymphocytes after vitamin C supplementa-
tion in healthy volunteers [25, 35, 36], whereas others
have shown no change [37] or even yielded mixed results
with a decreased in some types of oxidized DNA bases
and an increase in others [38, 39]. However, this inconsis-
tency is likely due to technical problems associated with
gas chromatography-mass spectrometry analysis in some
studies [38, 39]. HPLC-EC detection method used in the
present study appears to be gaining favor on account of
its minimal ex vivo oxidation artifacts and low basal lev-
els of oxidative DNA damage. The lymphocyte 8-OHdG
levels measured in our healthy subjects are much lower
than those by other investigators [40]. In addition, rig-
orous procedures, such as the addition of antioxidants
during isolation and hydrolysis of DNA, avoiding the use
of phenol, and storing samples under nitrogen, were em-
ployed in our study to minimize and control for sources
of experimental error [9, 10]. Another crucial point with
regard to human supplementation studies is that proper
placebo controls often are not included [38, 39]. To avoid
a questionable experimental design [20], our study has
been conducted with a proper placebo group throughout
the entire duration of the study.
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Fig. 4. Steady-state hOGG1 and hMTH1 mRNA levels analyzed by re-
verse transcriptase-polymerase chain reaction (RT-PCR) in peripheral
blood lymphocytes. Abbreviations are: M, marker; N, normal healthy
controls; U, uremic patients not receiving dialysis yet; and H, hemodial-
ysis patients. Quantitated data were expressed as the proportion of
the specific gene product to glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) product for expression of hOGG1 (A) and hMTH1
(B), respectively. Brackets indicate SD. aP < 0.05 vs. normal controls;
bP < 0.05 vs. undialyzed patients.
Numerous studies showed vitamin C inhibits oxidative
DNA damage in isolated or cultured cells exposed to ul-
traviolet visible light [41]; nevertheless, in vitro studies
are often confounded by the pro-oxidant effect of vita-
min C in the presence of free transition metals [42]. Since
vitamin C administration facilitates iron mobilization in
chronic hemodialysis patients [16–19], there are concerns
that it might promote electron exchange and enhance
iron toxicity to cellular constituents, especially in those
patients with increased iron stores. However, the hypoth-
esis is not supported by two recent human studies with
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Fig. 5. Expression of hOGG1 and hMTH1 mRNAs analyzed by re-
verse transcriptase-polymerase chain reaction (RT-PCR) in peripheral
blood lymphocytes of chronic hemodialysis patients with ferritin values
of<500 and ≥500 lg/L at 24 hours of vitamin C or placebo investigated.
Abbreviations are: M, marker; B, baselines; C, vitamin C treatment;
and P, placebo. Quantitated data were expressed as the proportion of
the specific gene product to glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) product for expression of hOGG1 (A) and hMTH1
(B), respectively. Brackets indicate SD. aP < 0.05 vs. baselines; bP <
0.05 vs. placebo.
vitamin C and iron cosupplementation to healthy subjects
[39, 43]. There is no overall increase in total DNA base
damage; furthermore, a significant decrease in leukocyte
8-OHdG levels was observed at the end of the two studies
[39, 43]. In our study a reduction in lymphocyte 8-OHdG
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levels and intracellular ROS production by vitamin C is
also demonstrated in chronic hemodialysis patients both
with normal and increased iron stores. Our data corrob-
orate their findings [39, 43] and reveal no compelling evi-
dence for a pro-oxidant effect of vitamin C on DNA base
damage in chronic hemodialysis patients, even in those
with increased iron stores.
In our study, following 8 weeks vitamin C supplemen-
tation, the generation of ROS by lymphocytes is reduced
significantly, showing that vitamin C is involved in the in-
hibition of ROS formation. This response is also observed
in glutathione-depleted HL-60 cells [44] and neutrophils
of chronic heart failure patients receiving long-term vita-
min C therapy [45]. Therefore, it seems unlikely that the
antioxidant effect of vitamin C relies only on its extracel-
lular scavenging effect. Vitamin C is actively transported
into cells through an insulin-dependent transport system
[46]. There is a wide range of intracellular concentrations
of vitamin C in human cells and tissues. Levine et al [47]
found that lymphocytes accumulate 3.5 mmol/L ascorbic
acid at oral intake of 100 to 200 mg of vitamin C daily,
which corresponds to a plateau plasma concentration of
56 to 66 lmol/L. In the present study, plasma concen-
tration of vitamin C is less than 50 lmol/L prior to sup-
plementation, indicating that intracellular vitamin C in
lymphocytes of chronic hemodialysis patients is not sat-
urated at baseline. After 8 weeks of supplementation,
plasma vitamin C concentration increases to a mean
level of 88.4 lmol/L, at which saturates lymphocyte vi-
tamin C levels. Thus, scavenging effects of vitamin C
may be mainly intracellular. An inhibition of ROS pro-
duction points to that vitamin C is primarily responsi-
ble for neutralizing ROS to prevent cellular DNA from
damage. In addition, ROS-induced DNA oxidation is
likely due to generated intermediate free radicals, and
vitamin C may have its major quenching effect at this
level. Paradoxically, Chen et al [48] reported that, at
higher concentrations such as 103 and 104 lmol/L, vi-
tamin C induces ROS generation determined in vitro
by lucigenin-enhanced chemiluminescence (LucCL) as-
say when mixed with plasma or whole blood of healthy
subjects and hemodialysis patients. However, vitamin C
at a physiologic concentration of 100 lmol/L cannot sig-
nificantly enhance LucCL intensity. Reasons of different
vitamin C concentrations, study protocols (i.e., 8 weeks of
supplementation vs. a single bolus injection after a dialy-
sis session) and assays for ROS detection (i.e., DCF-DA
assay vs. LucCL assay) may possibly account for the vari-
ance in vitamin C behavior in different compartments
(i.e., intracellular in vivo vs. extracellular in vitro).
hOGG1 and hMTH1 have been identified to be in-
volved in repair of DNA containing the oxidized base
of 8-OHdG. hOGG1 removes 8-OHdG from DNA
by breaking the glycosidic bond of 8-OHG residue
from oxidatively damaged DNA and cleaving the phos-
phadiester bond at the resulting apurinic site via b
elimination [21, 22]. hMTH1 prevents the incorpo-
ration of 8-OHG into cellular DNA by hydrolyzing
8-OH-deoxyguanosine triphosphate (dGTP) to 8-OH-
deoxyguanosine monophosphate (dGMP) [23, 24]. Sev-
eral groups have shown that both 8-OHdG levels and its
repair are induced in human leukocytes and rat kidney
by oxidative stress [49, 50]. Therefore, in addition to an-
alyzing lymphocyte 8-OHdG, it is of interest to assess its
repair. In the current study we have demonstrated that
hOGG1 is inducible at the mRNA level by hemodialy-
sis in peripheral lymphocytes and its level is higher than
those of undialyzed patients and healthy controls. Fur-
thermore, gene expression of hOGG1 is elevated follow-
ing vitamin C administration for 24 hours and remains
higher than the level after placebo treatment in both
chronic hemodialysis patients of normal and increased
iron stores. Increased mRNA levels of DNA repair gene
may not necessarily reflect increased DNA repair enzyme
activity. However, investigators have proposed that high
hOGG1 mRNA levels are associated with high repair of
8-OHdG [51, 52]. Accordingly, up-regulation of hOGG1
expression by vitamin C seen in the current study may be
linked to the increase in 8-OHdG repair enzyme activity,
suggesting that the decrease in 8-OHdG levels of lympho-
cyte DNA may be attributed partially to the activation of
hOGG1 after vitamin C supplementation. Cooke et al
[25] disclosed a significant decrease in 8-OHdG levels in
peripheral mononuclear cell DNA, followed by a sequen-
tial, significant increase in the levels of serum and urine
8-OHdG from healthy subjects undergoing supplemen-
tation with 500 mg/day vitamin C. The oxidatively dam-
aged deoxynucleotides generated in the repair processes
may subsequently be enzymatically hydrolyzed to stable,
water-soluble deoxynucleosides and finally excreted in
the urine. The findings of Cooke et al [25] and in our study
suggest that vitamin C promotes the removal of 8-OHdG
from DNA via the up-regulation of repair enzymes, and
thereby demonstrate a nonscavenging antioxidant effect.
Expression of hMTH1 has been reported in human
cancer cell lines [53, 54], indicating upregulation of
hMTH1 gene expression in cancer cells with high lev-
els of oxidative stress. In this study we have also found
that the mRNA level of hMTH1 maintains higher than
the healthy control level. But hMTH1 gene expression is
not regulated by vitamin C administration for 24 hours
in chronic hemodialysis patients. Our observations sug-
gest that although vitamin C may be important in the
up-regulation of hOGG1 gene expression for removal of
8-OHdG from oxidatively damaged DNA in peripheral
lymphocytes of chronic hemodialysis patients, it does not
appear to play a role in the regulation of hMTH1 gene
expression. The difference is unknown and further stud-
ies are needed to understand the molecular mechanisms
of this regulation.
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